Arvinas and Pfizer’s Vepdegestrant Shows Significant Improvement in Progression-Free Survival for …

Arvinas and Pfizer have released detailed findings from the Phase 3 VERITAC-2 clinical trial, revealing interesting advances in the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The trial compared vepdegestrant monotherapy with fulvestrant in adults whose cancer had progressed after prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy.

The results, which were shared during an American Society of Clinical Oncology (ASCO®) press briefing and identified as Best of ASCO, indicated a significant improvement in progression-free survival (PFS) for patients with an estrogen receptor 1 (ESR1) mutation. Vepdegestrant demonstrated a 43% reduction in the risk of disease progression or death compared to fulvestrant, with a median PFS of 5.0 months versus 2.1 months for fulvestrant.

Erika P. Hamilton, M.D., Director of Breast Cancer Research at the Sarah Cannon Research Institute, expressed optimism about the results, suggesting that vepdegestrant could provide a beneficial treatment option for patients with ESR1 mutations, a population that often faces resistance to standard therapies. Furthermore, she noted the favorable safety profile of vepdegestrant in the trial, with low rates of gastrointestinal adverse events compared to fulvestrant.

John Houston, Ph.D., the CEO and President of Arvinas, highlighted the potential of vepdegestrant as a leading monotherapy option for patients with ESR1 mutations in the second-line setting based on the encouraging data from the VERITAC-2 trial. The trial’s secondary endpoints, such as clinical benefit rate (CBR) and objective response rate (ORR), also showcased positive outcomes with vepdegestrant compared to fulvestrant.

Johanna Bendell, M.D., Pfizer’s Chief Oncology Development Officer, emphasized the significance of vepdegestrant in combating treatment resistance associated with ESR1 mutations, offering hope for improved outcomes for patients facing this challenge. Approximately 2.3 million new breast cancer diagnoses were reported globally in 2022, underscoring the urgent need for effective treatments in this critical area of oncology.

The partnership between Arvinas and Pfizer in developing vepdegestrant signifies a pioneering approach to treating ER+/HER2- breast cancer by utilizing an investigational oral PROTAC ER degrader. This innovative therapeutic strategy leverages the body’s natural protein disposal mechanisms to target and degrade the estrogen receptor, marking a promising avenue in the fight against breast cancer.

In conclusion, the findings from the VERITAC-2 trial offer a glimpse of hope for patients with advanced breast cancer, particularly those with ESR1 mutations. The potential of vepdegestrant as a best-in-class treatment underscores the strides being made in advancing personalized and effective therapies for individuals facing challenges in their cancer journey.